IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio, Inc. (Nasdaq: INAB) has partnered with the UofL Health - Brown Cancer Center for exclusive access to a GMP manufacturing facility, essential for its INB-400 Phase 2 clinical program targeting glioblastoma. This collaboration aims to enhance efficiency in T-cell therapy production, addressing a significant bottleneck for cell therapy companies. The partnership potentially allows for future expansion into commercial-scale manufacturing, supporting broader access to innovative immunotherapies for cancer patients.
IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will participate in a fireside chat at the H.C. Wainwright & Co. 24th Annual Global Investment Conference on September 14, 2022, at 10:30 a.m. ET. The event will be live-streamed on the IN8bio website, with a replay available for 90 days. IN8bio specializes in gamma-delta T cell therapies for cancer, focusing on innovative treatments for glioblastoma and leukemia. The company is conducting Phase 1 trials for its lead products, INB-200 and INB-100, while exploring preclinical programs for various solid tumors.
IN8bio, Inc. (Nasdaq: INAB) has appointed Dr. Michael R. Bishop to its Scientific Advisory Board. Dr. Bishop is a renowned expert in cellular therapy and oncology, currently serving at the University of Chicago. His extensive experience in hematologic malignancies and stem cell transplantation is expected to bolster IN8bio’s development of gamma-delta T cell therapies. The company is advancing its clinical programs, including Phase 1 trials for glioblastoma and leukemia treatments, leveraging its DeltEx platform, which aims to enhance the efficacy of cell therapies.
IN8bio, Inc. (Nasdaq: INAB) announced its participation in several key conferences throughout September 2022. CEO William Ho will join the Cell Therapy Panel at Citi’s Annual BioPharma Conference in Boston on September 7. He will also partake in a Fireside Chat at H.C. Wainwright from September 12-15, with a session on September 14. Kate Rochlin, COO, will present at the BioProcess International Conference in Boston on September 28. Additionally, Lawrence Lamb, CSO, will present at the Sixth International Cancer Immunotherapy Conference in New York on September 30. IN8bio focuses on gamma-delta T cell therapies.
IN8bio, Inc. (Nasdaq: INAB) has reported that the underwriter of its recent public offering, which closed on August 16, 2022, partially exercised its option to purchase 268,949 additional shares at $1.90 each, adding approximately $0.5 million in gross proceeds. This brings the total number of shares sold to 5,663,686, with gross proceeds now totaling around $10.75 million. The offering was conducted under a registration statement declared effective on August 11, 2022.
IN8bio, Inc. (Nasdaq: INAB) successfully closed an underwritten public offering of 5,394,737 shares of its common stock at $1.90 per share, generating approximately $10.25 million in gross proceeds. The offering, managed by H.C. Wainwright & Co., included a 30-day option for the underwriter to purchase an additional 657,894 shares. This transaction was facilitated through a registration statement filed with the SEC, effective August 11, 2022. The funds are intended to support the company's clinical development of gamma-delta T cell therapies.
IN8bio recently announced a preclinical program for iPSC-derived gamma-delta T cells, presenting findings at the ASGCT Annual Meeting. The Phase 1 trial of INB-200 showed five of six patients exceeded expected progression-free survival (PFS), while two surpassed overall survival (OS) benchmarks. INB-100 Phase 1 trial data revealed two of three leukemia patients relapse-free at two years. The company appointed new executives to bolster its management team. Financially, R&D expenses rose to $3.5 million, with a net loss of $7.2 million for Q2 2022, and cash reserves decreased to $25.7 million.
IN8bio announced a public offering of 5,394,737 shares at $1.90 each, expected to close by August 16, 2022. The offering could generate approximately $10.25 million before expenses. H.C. Wainwright & Co. is the sole book-running manager, with an option for additional 657,894 shares. The registration statement was declared effective on August 11, 2022. IN8bio focuses on innovative gamma-delta T cell therapies for tumors, emphasizing its DeltEx platform's capabilities.
IN8bio, Inc. (Nasdaq: INAB) announced promising progress in its Phase 1 trial of INB-100 for high-risk relapsed acute myeloid leukemia (AML) patients. All three patients treated remain alive and disease-free for more than one year post-transplant, with two patients exceeding two years in complete remission. The therapy shows a manageable safety profile, with no severe adverse effects or dose-limiting toxicities reported. The data suggests potential for improved cure rates in AML without significant added risks, with further patient data expected later in 2022.
IN8bio, Inc. (Nasdaq: INAB) announced the issuance of a new European patent covering its Drug Resistant Immunotherapy (DRI) platform, expanding its intellectual property to include NK cells alongside gamma-delta T cells. This patent enhances IN8bio’s position in developing cellular therapies for solid tumors, emphasizing its innovative approach to combat cancer through genetically engineered immune cells. The company is actively advancing its pipeline, including ongoing Phase 1 trials for INB-200 and INB-100, aimed at treating glioblastoma and leukemia, respectively.